Aurobindo Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹64.00₹60.34₹59.81₹54.16₹32.90
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹64.00₹60.34₹59.81₹54.16₹32.90
₹652.39₹652.39₹562.21₹509.35₹458.10
₹601.50₹579.43₹546.21₹495.00₹424.23
—₹95.15₹67.57₹41.55₹40.74
₹41.70₹41.70₹24.19−₹19.24−₹5.69
—₹4.00₹0.00₹4.50₹7.50
58.158.158.158.658.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹95,530 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS32.9054.1659.8160.3464.00
Diluted EPS32.9054.1659.8160.3464.00
Book Value per Share458.10509.35562.21652.39652.39
Revenue per Share424.23495.00546.21579.43601.50
Cash Flow per Share40.7441.5567.5795.15—
Free Cash Flow per Share-5.69-19.2424.1941.7041.70
Dividends per Share7.504.500.004.00—
Shares Outstanding (cr)58.658.658.158.158.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.